Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

4.8%

1 terminated/withdrawn out of 21 trials

Success Rate

95.2%

+8.7% vs industry average

Late-Stage Pipeline

71%

15 trials in Phase 3/4

Results Transparency

85%

17 of 20 completed trials have results

Key Signals

17 with results

Enrollment Performance

Analytics

Phase 3
10(50.0%)
Phase 4
5(25.0%)
Phase 1
4(20.0%)
Phase 2
1(5.0%)
20Total
Phase 3(10)
Phase 4(5)
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT01550003Phase 3Completed

Pediatric Arthritis Study of Certolizumab Pegol

Role: lead

NCT02552212Phase 3Completed

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Role: lead

NCT01243177Phase 3Completed

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Role: lead

NCT02505542Phase 3Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Role: lead

NCT02276053Completed

Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

Role: lead

NCT01782222Phase 4Completed

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Role: lead

NCT00552344Phase 3Completed

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Role: lead

NCT01087788Phase 3Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Role: lead

NCT01087762Phase 3Completed

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Role: lead

NCT01465997Phase 3Completed

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Role: lead

NCT00596752Phase 4Completed

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

Role: lead

NCT02230904Phase 1Completed

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

Role: lead

NCT01744496Phase 4Completed

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Role: lead

NCT01537042Phase 3Completed

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Role: lead

NCT01854216Phase 1Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

Role: lead

NCT01761526Phase 1Completed

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

Role: lead

NCT01796938Phase 1Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects

Role: lead

NCT01723904Phase 3Completed

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Role: lead

NCT01711866Phase 4Completed

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Role: lead

NCT01455012Phase 4Completed

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome

Role: lead